Phagenesis Receives FDA Breakthrough Device Designation For Its Phagenyx® System To Accelerate Removal Of The Breathing Tube By Treating Neurogenic Dysphagia
January 2020
FDA’s Breakthrough Device Designation Program allows for priority review of the Phagenyx® System Manchester, England, 14 January 2020 – Phagenesis Ltd., a pioneering leader in the treatment of dysphagia, is pleased to announce today that the company has received Breakthrough … Continue reading